Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Other Neutral

Zero Candida announced officially been granted Patent No. 12654025B2 -- a meaningful milestone that reflects our commitment to innovation, technology, and long-term impact

By The Northwire Desk — AI Analysis Jun 24, 2026 · 08:00 ZCT · 0.14 Zero Candida Technologies Inc.
ZCT · Price

Executive Summary

  • Zero Candida Technologies, Inc. officially announced the grant of Patent No. 12654025B2, marking a significant milestone in its development of next-generation FemTech medical devices.
  • The patent covers the ZC-001, a smart, AI-enabled therapeutic device designed for the at-home treatment of Vulvovaginal Candidiasis (VVC) using precision blue light therapy, targeted drug delivery, and wireless diagnostics.
  • The technology is positioned to integrate advanced AI capabilities for disease detection, direct physician reporting, and automated pharmacy ordering, targeting a VVC treatment market projected to exceed US $2B by 2030.

Key Details

  • Patent Number: 12654025B2
  • Device Name: ZC-001
  • Core Technology: Integrates precision blue light therapy, targeted drug delivery, and wireless diagnostics for personalized at-home care.
  • Target Indication: Vulvovaginal Candidiasis (VVC), with a specific focus on recurrent (four or more episodes per year) and drug-resistant infections.
  • AI & Connectivity Features: Designed to evolve with AI capabilities to treat fungal infections, detect new diseases, report diagnostic data directly to physicians, and automatically order medication from pharmacies.
  • Clinical & Operational Rationale: Aims to improve patient outcomes, reduce the need for repeated in-clinic visits, and address a condition affecting approximately 75% of women globally.
  • Market Projection: The VVC treatment market is projected to exceed US $2 billion by 2030.
  • Company Tickers: TSXV: ZCT, OTCQB: ZCTFF, FSE: 9L2
Read the original news release →

More from Zero Candida Technologies Inc.

Feb 17, 2026 · 08:00

Zero Candida Scales Production to 250 ISO 13485 Clinical-Grade Prototypes of ZC-001 Therapeutic Device

Production / Operations Oct 20, 2025 · 09:00

Zero Candida Achieves Design Freeze and Begins Prototype Production of ZC-001 Therapeutic Device

Production / Operations